B iological discovery is very much dependent on technological innovation, and often the reverse is true too. Up to relatively recently, research has had to adopt a reductionist approach to biological discovery, that is, one focusing on a single gene, protein, pathway, etc, because of the constraints imposed by the available tools of discovery. Nowadays, the increasingly sophisticated nature of our current tools and the advances made in computing science and information technology are ushering us into a new era, one of systems biology 1 and, possibly, personalized medicine. 2
B iological discovery is very much dependent on technological innovation, and often the reverse is true too. Up to relatively recently, research has had to adopt a reductionist approach to biological discovery, that is, one focusing on a single gene, protein, pathway, etc, because of the constraints imposed by the available tools of discovery. Nowadays, the increasingly sophisticated nature of our current tools and the advances made in computing science and information technology are ushering us into a new era, one of systems biology 1 and, possibly, personalized medicine. 2
Article, see p 1138
MicroRNA (miRNA), a family of short noncoding RNAs that inhibit gene expression at the post-transcriptional level by targeting mRNA for degradation or repression, is now understood to be a major regulatory element of biological systems. 3 The uncovering of miRNA-mediated regulation is greatly advancing our understanding of how biological processes are controlled and has fuelled the promise of improved therapeutics for difficult-to-treat, and even currently untreatable, pathologies. But, because of the very nature of how miRNAs work, that is, as finetuners within a regulatory network, studying them not only individually, but also isolated from the rest of the cellular regulatory apparatus cannot provide us with all the answers, or, rather, the solutions, we are looking for and need. For this reason, miRNAs should be studied above all from the systems biology perspective, whereby the nonlinear interactions inherent in the multiple biomolecular components that make up the cell can be appreciated and taken into account. To do this, most, if not all, of the components of a given subsystem and its regulatory networks would probably need to be characterized. 4 In this way, we can better understand how pathways and regulatory networks interconnect, how they develop and evolve temporally, and how they are involved in pathogenesis.
The importance of systems biology is brought especially into focus when applied to diseases with complex cause, such as those of the cardiovascular system. Although many advances have been recently made in the management of cardiovascular pathologies, such as heart failure, they remain a major cause of morbidity and mortality worldwide due not only to problems related to healthcare but also to incomplete understanding of the underlying pathobiology. 5 Arguably, the current paucity of novel, improved therapeutics is being caused by the lack of a holistic view of disease. 6 A major challenge for drug discovery today is, therefore, to start from an in-depth understanding of the underlying pathogenesis and, from there, work toward novel treatments.
Several approaches can be used to study the effect of miR-NAs on the cardiovascular system at the genome-wide level. Among these, quantitative mass spectrometry is especially instructive in that it not only has the potential to identify the miRNA targetome in its entirety but, because it focuses on the proteome rather than the transcriptome, it can also pick up translationally repressed targets as well as those downregulated after mRNA degradation. 7 Tandem reports by the laboratories of Bartel and Rajewsky were the first to describe the application of quantitative mass spectrometry to miRNA research. 8, 9 More recently, our laboratory used multidimensional protein identification technology to identify which components of the cardiomyocyte secretome are substrates of miR-1, a highly expressed cardiac miRNA. 10 In the current issue of Circulation Research, Abonnenc et al 11 use a similar approach to further the understanding of the role of the cardiac fibroblast (CFB) in cardiac pathophysiology; they used liquid chromatography/tandem mass spectrometry to analyze the secretome of CFBs and assess the effects of miR-29b 12 and miR-30c 13 -2 highly expressed CFB miRNAs involved in cardiac fibrosis ( Figure) -on its composition. Abonnenc et al 11 report that mouse CFBs grown in vitro can secrete up to 248 extracellular proteins under basal (serum-starved) conditions and 186 proteins after stimulation with transforming growth factor-β1, a main fibrogenic protein. 14, 15 As was to be expected, the secreted proteins were mainly involved in extracellular processes and consisted of glycoproteins, cytokines/growth factors, proteases and their inhibitors, and collagens, among others. miR-29 affected the FB secretome to a greater extent compared with miR-30c, modulating 46 proteins (67% of which were downregulated) in contrast to only 14 proteins (71% of which were downregulated) of the secretome, when a >30% fold-change cut-off limit was used. Of note, only 39% and 14% of the regulated proteins were targets predicted for, respectively, miR-29b and miR-30c by at least one bioinformatics algorithm (TargetScan, PicTar, or DIANA MicroT). In addition, because stress alters the response to miRNAs, the authors studied the effect of miR-29b on the transforming growth factor-β1-stimulated secretome, finding 28 significantly altered proteins (75% were downregulated), 50% of which were not predicted targets. Three predicted miR-29b targets-insulin-like growth factor-1, leukemia inhibitory factor, and pentraxin-related
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protein-3-were confirmed by ELISA and qPCR to be direct targets of the miRNA, and in vivo treatment with antagomiR-29b increased the levels of insulin-like growth factor-1 in mouse heart and serum. The authors then go on to provide functional data on the roles of miR-29b and miR-30c. Conditioned medium from miR-29b-overexpressing CFBs inhibited the adhesion of cardiomyocytes onto glass coverslips; reduced the expression of the sarcomeric proteins troponin I, α-actinin, and myosin-binding protein C; and induced an atrophic cell state. Conditioned medium from miR-30c-overexpressing CFBs was less effective in inhibiting cardiomyocyte adhesion, did not reduce the expression of sarcomeric proteins, and induced cell hypertrophy. Overexpression of miR-29b in CFBs inhibited their expression of miR-30c, similarly as exposure to transforming growth factor-β1. In vivo, miR-29b expression was not reduced in the myocardium of mice after 14 days of induced pressure overload, in contrast to other miR-29 family members and to miR-30c, which were repressed. When mice were treated with an antagomiR-29b before induction of pressure overload, perivascular fibrosis was increased, but chamber volumes, wall thicknesses, and cardiac function were not affected negatively any further.
Improving our understanding of CFB biology and the role of fibrosis in the pathogenesis of cardiac hypertrophy and failure is essential. In fact, although cardiomyocytes account for most of the volume of the myocardium and represent the most relevant cell type of the heart at the functional level, CFBs numerically comprise a majority of the heart's cells, are a major determinant of myocardial extracellular matrix and homeostasis, and are active players in cardiac pathology. 16 Since the discovery of miRNAs, much effort has been spent deciphering the role of these regulators also for CFB function. 17 In essence, the article by Abonnenc et al 11 provides an extensive data set of CFB-secreted protein components and illustrates how 2 fibrosis-related miRNAs affect CFB protein secretion under basal and stressed conditions (Figure) . The data set reveals the presence of both direct (primary) and indirect (secondary and tertiary) targets, many of which are not, or cannot be, identified by the computer programs dedicated to miRNA targeting. This is an important step in generating the maps we need today to improve our understanding of the intricate interactive networks underlying myocardial biology and, as a consequence, cardiovascular pathology. However, because this proteomics study concentrated on the secretome, it does not identify regulatory mechanisms other than direct miR-29b/miR-30c-mediated inhibition that might have been brought to light through the analysis of the CFB cytoproteome and miRNome. A hint of the importance of this is given by their interesting finding of miR-29b-miR-30c cross-talk, 11 a rare instance, at least to date, of a miRNA regulating another miRNA, and a phenomenon that may amplify the effects of a given miRNA. 18 Future steps call for the integration of intra-and extra-cellular CFB proteomic data with the CFB miRNome and the combination of findings with those of other cell types constituting the myocardium.
Recent technological advances are improving our understanding of pathophysiology at an increasingly rapid rate. As illustrated by the article by Abonnenc et al, 11 it is now possible to quantitatively and qualitatively characterize hundreds, if not thousands, of proteins relatively easily in one fell swoop. Importantly, differences highlighted by comparing data obtained under different settings can reveal details of the underlying regulatory mechanisms. However, in parallel with the often overwhelming wealth of novel and high-quality information they provide, the increasingly sophisticated tools we have at hand introduce many new problems too. For example, sample characterization and standardization are ever more critical as the accuracy of the measurements taken increases and comparisons with other studies are needed. In fact, furthering clinical medicine today requires the integration of 3 approaches to drug discovery: the deposition of high-throughput omic data in online databases, which must permit not only interstudy comparisons but also the integration of data on different subnetworks obtained from diverse platforms (a bottom-up approach); the development of computer modeling of organs and disease (a top-down approach); and the use of complex, human-and, ideally, patient-specific-in vitro Figure. Schematic of some of the differential networking effects of miR-29 and miR-30. (1) Pressure overload downregulates miR-29a and miR-29c but, in contrast to myocardial infarction, does not downregulate miR-29b, indicating that cardiovascular diseases may induce cardiac hypertrophy and heart failure through differing mechanisms. (2) Inhibition of miR-29b with an antagomiR produces more perivascular fibrosis, indicating that miR-29 family members may have different regional effects on fibrosis. (3) miR-29b inhibits miR-30c, an example of miRNA-miRNA regulation. (4) Fibroblasts and cardiomyocytes express miR-30c, and downregulation of this miRNA removes repression on the prohypertrophic protein connective tissue growth factor (CTGF), an example of a synergistic effect between cardiomyocytes and fibroblasts. (5) Alteration of the fibroblast secretome can affect the expression of cardiomyocyte proteins through the action of soluble factors, an example of fibroblast-cardiomyocyte cross-talk. ACTN indicates α-actinin; CM, cardiomyocyte; FB, fibroblast; IGF-1, insulin-like growth factor-1; LIF, leukemia inhibitory factor; MYBPC, myosinbinding protein C; TGF-β1, transforming growth factor-β1; and TNNI, cardiac troponin I. systems for drug experimentation and testing (such as induced pluripotent stem cell technology). These different technologies necessarily need to be implemented by multidisciplinary teams of scientists. Although significant progress is being made, many hurdles still need to be overcome if we are to make any medical headway in this postgenomic era and fully complete the paradigm shift away from a predominantly minimalistic view of the disease process.
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